Bayer Gears Up for US Launch of Sunharbo After Landmark FDA Clearance
Published on 11/17/2026 at 13:02 | Editorial boerse-global.deBayer is preparing to ship its newly approved stroke prevention drug SUNHARBO to the United States between mid and late November, following the FDA's green light for the treatment in the prior week. The approval covers adults who have recently suffered a non-cardioembolic ischemic stroke or a high-risk transient ischemic attack (TIA), with the 50 mg dose cleared for use alongside antiplatelet therapy.
The German group has billed asundexian — the active ingredient behind SUNHARBO — as the world's first approved Factor XIa inhibitor, a mechanism making its debut in a sanctioned medicine. The FDA decision, dated 10 November, targets the reduction of recurrent stroke risk and rests on data from the Phase 3 OCEANIC-STROKE trial.
A Second Approval in Quick Succession
Bayer's pipeline delivered more than one win in November. Chinese regulators cleared sevabertinib as a first-line treatment for patients with HER2-mutated non-small cell lung cancer — a green light spanning a different patient population and therapeutic area than the US stroke approval.
Should investors sell immediately? Or is it worth buying Bayer?
Guidance Raised on Solid Third-Quarter Figures
Alongside its third-quarter 2026 results, the company lifted its full-year outlook. Bayer now projects EBITDA before special items of EUR 9.8 billion to EUR 10.3 billion on a currency-adjusted basis. For the reporting quarter, group revenue came in at EUR 10.1 billion, with EBITDA before special items of EUR 1.62 billion — both higher than a year earlier, according to the company.
Deutsche Bank Turns More Bullish
Deutsche Bank Research raised its price target on Bayer from EUR 60 to EUR 65 last Tuesday, media reports indicated, while reaffirming its buy rating. Analyst Virginie Boucher-Ferte lifted her EBITDA and earnings-per-share estimates for 2027 and 2028 in the wake of the quarterly figures.
Roundup Litigation Back in Focus
On the legal front, a US federal judge was reported yesterday to be reviewing which Roundup claims may proceed following a Supreme Court ruling, a check that bears on the litigation landscape surrounding Monsanto's glyphosate-based herbicide and on how individual cases against Bayer move forward.
Ad
Bayer Stock: New Analysis - 17 November
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
